Recent 8-K filings for IVDA
Highest-materiality recent filing
Iveda Solutions restates 2023 & 2024 financials; net losses increase by $1.4M-$1.6M
- Restatement due to multiple errors including improper capitalization of software dev costs, deferred tax asset write-off, and intercompany payable.
- Net loss for nine months ended Sep 30, 2023 restated to $2.68M from $2.14M; loss per share changed from $0.13 to $0.27.
-
Iveda Solutions receives Nasdaq bid price deficiency notice; has 180 days to comply
Nasdaq letter on March 6, 2026, cites failure to maintain $1 minimum bid price for 30 consecutive business days.
-
Iveda raises ~$2M in public offering of 5.7M shares and 11.4M warrants at $0.35/unit
Offering of 5,259,999 shares (or pre-funded warrants for 454,287 shares) and series X warrants for 11,428,572 shares at $0.35/unit.
-
Iveda Solutions holds 2024 Annual Meeting; re-elects four directors
Re-elected directors Farnsworth, Franco, Gillen, Ly; each received ~503k-508k votes for, ~52k-57k withheld.
-
Iveda Solutions regains Nasdaq compliance on equity requirement
Nasdaq previously warned company for failing $2.5M stockholders' equity minimum.
-
Iveda Solutions shareholders approve issuance of 1.25M warrants at $3.44 per share
Shareholders approved Proposal 5 to issue 625,000 Series A and 625,000 Series B warrants with a $3.44 exercise price.
-
Nasdaq grants Iveda Solutions extension to Nov 24, 2025 to regain equity compliance
Stockholders' equity of $1.7M as of March 31, 2025 fell below Nasdaq's $2.5M minimum.
-
Iveda Solutions' 2024 Annual Meeting fails to approve warrant issuance; adjourned to Aug 29
At reconvened 2024 Annual Meeting on June 2, 2025, Proposal 5 (issuance of 625K Series A and B warrants and underlying shares) did not receive sufficient votes.
-
Iveda receives Nasdaq deficiency notice for stockholders' equity below $2.5M
As of March 31, 2025, stockholders' equity was $1.7M, below Nasdaq's $2.5M minimum.
-
Iveda Solutions restates 2023 & 2024 financials; net losses increase by $1.4M-$1.6M
Restatement due to multiple errors including improper capitalization of software dev costs, deferred tax asset write-off, and intercompany payable.
-
Iveda shareholders approve redomicile to Delaware; warrant issuance vote adjourned to June 2
Redomicile from Nevada to Delaware approved: 1,233,381 for, 21,273 against, 19,553 abstained.
-
Iveda Solutions enters ATM offering agreement with H.C. Wainwright for up to $5.08M in common stock
Agreement with H.C. Wainwright & Co. to sell up to $5,082,431 of common stock in at-the-market offerings.
-
Iveda Solutions dismisses Kreit & Chiu CPA LLP, appoints Weinberg & Company as auditor
Dismissed Kreit & Chiu CPA LLP as independent auditor effective February 21, 2025.
-
Stockholders re-elected directors Farnsworth, Franco, Gillen, Ly (615-34K for each).
-
Iveda Solutions 1-for-8 reverse stock split effective Sept 17, 2024 to meet Nasdaq bid price rule
1-for-8 reverse stock split expected effective at market open on September 17, 2024; shares to trade under same symbol IVDA with new CUSIP 46583A303.
-
Iveda Solutions effects 1-for-4 reverse stock split, authorized shares cut to 9.375M
Reverse stock split at 1:4 ratio; outstanding shares drop from ~18.07M to ~4.52M.
-
Iveda Solutions raises ~$2.15M in registered direct offering and private placement
Sold 1.8M shares at $0.43/share and pre-funded warrants for 3.2M shares at $0.429/warrant; gross proceeds ~$2.15M.
-
Iveda dismisses BF Borgers as auditor after SEC order; appoints Kreit & Chiu
Dismissed BF Borgers CPA PC on May 9, 2024, following SEC administrative order dated May 3, 2024.
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material